Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node (2019) Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Sunderkötter C, Kaatz M, et al. Journal article Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group (2019) Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, et al. Journal article Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto (2019) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Journal article Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study (2019) Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, et al. Journal article Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation (2019) Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, Michonneau D, et al. Journal article Pretreatment Vitamin D deficiency is associated with impaired progression-free and overall survival in hodgkin lymphoma (2019) Borchmann S, Cirillo M, Goergen H, Meder L, Sasse S, Kreissl S, Broeckelmann PJ, et al. Journal article Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT) (2018) Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, et al. Journal article Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 (2018) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study (2018) Fasching P, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, et al. Journal article Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) (2018) Untch M, Von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P, Tesch H, et al. Journal article